Lazertinib

Catalog No.S8724 Synonyms: YH25448,GNS-1480

For research use only.

Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4.

Lazertinib Chemical Structure

CAS No. 1903008-80-9

Selleck's Lazertinib has been cited by 3 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Other EGFR Products

Biological Activity

Description Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4.
Targets
Del19/T790M [1]
(Cell-free assay)
L858R/T790M EGFR [1]
(Cell-free assay)
Del19 [1]
(Cell-free assay)
L85R [1]
(Cell-free assay)
WT EGFR [1]
(Cell-free assay)
1.7 nM 2 nM 5 nM 20.6 nM 76 nM
In vitro

Lazertinib targets the activating EGFR mutations Del19 and L858R, as well as the T790M mutation, while sparing wild type. In NSCLC cell lines and primary cancer cells from patients harboring EGFR mutations, YH25448 more potently inhibits cancer cell growth and significantly increases tumor cell apoptosis compared to osimertinib[1]. In the cell proliferation assays, GI50 values of lazertinib are 6 nM, 5 nM, and 711 nM for H1975 cells (L858R/T790M), PC9 cells (del19) and H2073 cells (wt), respectively[2].

In vivo

In an in vivo mouse model implanted with H1975 cells, once-daily YH25448 treatment results in indramatic dose-dependent tumor regression in both subcutaneous and intracranial lesions with no abnormal signs such as skin keratosis. The plasma half-life of YH25448 is 5.9-6.8 hr, while the tumor to plasma AUC0-last ratio is 3.0-5.1 in tumor-bearing mice. YH25448 shows excellent penetration of the blood-brain bartier, achieving CSF concentrations exceeding the IC50 value for pEGFR inhibition. YH25448 shows superior efficacy for tumor regression in an EGFR mutant brain metastasis model[1].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Ba/F3 cells
  • Concentrations: 5, 10, 100 nM
  • Incubation Time: 6 h
  • Method:

    Ba/F3 cells overexpressing the indicated EGFR mutant are treated with YH25448 or osimertinib for 6 hours at the indicated concentrations. pEGFR levels are detected by Western blot analysis.

  • (Only for Reference)
Animal Research:

[1]

  • Animal Models: An intracranial tumor growth model (BALB/c nude mice inoculate with H1975-luc cells)
  • Dosages: 10 and 25 mg/kg
  • Administration: --
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 4 mg/mL
(7.21 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 554.64
Formula

C30H34N8O3

CAS No. 1903008-80-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04410094 Completed Drug: Lazertinib|Drug: Itraconazole|Drug: Rifampin Healthy Janssen Research & Development LLC September 14 2020 Phase 1
NCT04410081 Completed Drug: 14C-lazertinib Healthy Janssen Research & Development LLC July 14 2020 Phase 1
NCT04075396 Active not recruiting Drug: Lazertinib Carcinoma Non-Small-Cell Lung Janssen Research & Development LLC|Yuhan Corporation October 16 2019 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lazertinib|Lazertinib ic50|Lazertinib price|Lazertinib cost|Lazertinib solubility dmso|Lazertinib purchase|Lazertinib manufacturer|Lazertinib research buy|Lazertinib order|Lazertinib mouse|Lazertinib chemical structure|Lazertinib mw|Lazertinib molecular weight|Lazertinib datasheet|Lazertinib supplier|Lazertinib in vitro|Lazertinib cell line|Lazertinib concentration|Lazertinib nmr|Lazertinib in vivo|Lazertinib clinical trial|Lazertinib inhibitor|Lazertinib Protein Tyrosine Kinase inhibitor|Lazertinib smiles